@Lintin Just trying to think out of the box. What is an additional 10 million for multi-billion $ companies that could pay off bond holders and work with Echo technology and develop additional patents beyond glucose applications. If algorithms work for glucose, they can be developed for A1C, insulin or transdermal delivery. All would be applicable for companion DX. Why should we be at the mercy of PP or MTIA? Scrap AS and BOD and replace with thought leaders in other disciplines. Echo technology and patents can be a launching pad or foundations for other cutting edge technologies!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.